XPHOZAH expected to launch in Q4, pending FDA approval
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARDX:
- Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance
- Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023
- Ardelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference
- Ardelyx announces acceptance of NDA for tenapanor in China
- Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China